Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Global Blood Therapeutics Leaves ASH With Momentum Behind Voxelotor In Sickle Cell Disease

04 Dec 2018

• By Jessica Merrill

Anemia, sickle cell and normal red blood cell, 3d Illustration.

Related Content

Global Blood Makes Case For Accelerated Approval Of Sickle Cell Drug Voxelotor

28 Jun 2018

Case Studies: How Patient Input Is Changing R&D

09 Jan 2018

Related Companies

Global Blood Therapeutics, Inc.

Bluebird Bio

Additional Topics

Clinical Trials Regenerative Medicine Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.